Trial Profile
A Phase 1b Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Demcizumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 22 Jan 2016 Updated results from this trial were presented at the 2016 ASCO GI Symposium, according to an OncoMed Pharmaceuticals media release.
- 22 Jan 2016 Updated results from this trial published in an OncoMed Pharmaceuticals media release.